Arocell Company
%20.jpg)
Arocell develops and commercializes new and unique biomarker tests that can be used in the prognosis, monitoring, and follow-up of cancer. It has developed a test, the TK 210 ELISA for measuring the enzyme TK1, which is a protein that is elevated in the blood when there is increased cell turnover (cell growth and cell death) within the patient. The company was established in 2003 and is based in Uppsala, Sweden.
Founded Date:
2003-01-01
Last Funding Type:
Seed
Headquarters:
Uppsala, Uppsala Lan, Sweden
Investors Number:
1
Technology:
Biomarkers
Employee Number:
11-50
Industry:
Biotechnology, Health Care, Science and Engineering
Estimated Revenue:
Less than $1M
Investor Type:
For Profit
Total Funding:
$40K